Erika Van Landuyt

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Chloe Orkin, Jean‐Michel Molina, Eugènia Negredo et al. · The Lancet HIV · 2017 · 96 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients

Joseph J. Eron, Chloe Orkin, Joel E. Gallant et al. · AIDS · 2018 · 85 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Compassionate use of <scp>long‐acting</scp> cabotegravir plus rilpivirine for people living with <scp>HIV</scp>‐1 in need of parenteral antiretroviral therapy

Ronald D’Amico, Santiago Cenoz Gomis, Riya Moodley et al. · HIV Medicine · 2022 · 46 citations · Full text

Pharmacy, Clinical Pharmacy, Pharmacotherapy +17

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Joseph J. Eron, Chloe Orkin, Douglas Cunningham et al. · Antiviral Research · 2019 · 36 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients

Chloe Orkin, Joseph J. Eron, Jürgen K. Rockstroh et al. · AIDS · 2019 · 36 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17